Replay available

Diaceutics PLC (DXRX) Q4 2024 Earnings Call

Diaceutics PLC (LSE: DXRX) Q4 2024 earnings conference call, held 2025-05-13. Replay captured from the company's public earnings webcast.

Tue, May 13, 2025 at 10:30 AMendedReplay
Diaceutics PLC (DXRX) Q4 2024 Earnings Call

Investor webinar replay

Latest press releases

Companies on this event

Featured Presenters

Simon Ghilan

Investor Relations Manager

Nick Roberts

Chief Financial Officer

Ryan Keeling

Chief Executive Officer

Replay transcript excerpt

Good afternoon and welcome to the Diocetix PLC Final Results Investor presentation. Throughout this recorded presentation, investors will be in listen-only mode. Questions are encouraged and they can be submitted at any time using the Q&A tab situated on the right-hand corner of your screen. Simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all questions submitted today and publish responses where it is appropriate to do so. Before we begin, I would like to submit the following poll, and I would now like to hand you over to the team of Diocetics PLC. Good afternoon to you. Good afternoon, everybody, and welcome to today's call hosted by Diocetics to discuss the company's full year 2024 results issued earlier today. My name is Simon Ghilan, and I manage Diocetics' investor relations program. On the call today to discuss the results are Ryan Keeling, the Chief Executive Officer of Diocetics, and Nick Roberts, the company's CFO. Before I hand you over to Ryan for his formal remarks, I would draw your attention to the forward-looking statement slide in our presentation, which is on screen now and also available to download at InvestorMeetsCompanies and Diastetics.com. At this time, I will now turn the call over to Ryan Keeling. Ryan, go ahead, please. Thank you, Simon, and thank you all for joining us today. Good afternoon and good morning to those of you joining us from the US. i'm delighted to report on what was a great year in 2024 for diastetics and the format of today is i'll talk you through some top lines then i'm going to hand you over to nick to take a deeper dive into some of the financials and then i'll come back and do a bit of a re...

More from Diaceutics Plc